How does effective half-life influence radiation dose?
Effective half-life determines how long radioactive activity remains within a tissue, and therefore directly influences the total radiation dose delivered to that tissue.
Because radiation dose depends on the total number of decays over time (cumulated activity), a longer effective half-life results in greater cumulated activity and higher absorbed dose. Conversely, rapid biological clearance shortens effective half-life and reduces dose.
Effective half-life determines how long radioactive activity persists in tissue and therefore directly controls cumulated activity and absorbed dose.
Effective half-life is therefore one of the most important determinants of internal radiation dose in nuclear medicine.
Understanding the physics
Once a radiopharmaceutical is administered, activity in a tissue decreases due to two simultaneous processes:
Physical decay of the radionuclide
Biological elimination of the compound
These combine to produce the effective half-life, defined by:
1/Teff = 1/Tphys + 1/Tbio
Effective half-life governs the rate at which activity declines in a tissue. Since radiation dose depends on the total number of decays occurring over time, effective half-life directly influences cumulated activity, which is the area under the time–activity curve.
If effective half-life is long:
Activity persists
The time–activity curve declines slowly
The area under the curve increases
Cumulated activity increases
Absorbed dose increases
If effective half-life is short:
Activity falls rapidly
Cumulated activity decreases
Absorbed dose decreases
In diagnostic nuclear medicine, many tracers are designed with relatively short effective half-lives to limit patient dose while allowing sufficient imaging time.
In radionuclide therapy, prolonged retention in tumour tissue is desirable because it increases cumulated activity and therapeutic absorbed dose.
Effective half-life may vary between organs. For example, tumour retention may be long while blood clearance is rapid, increasing target-to-background ratio and therapeutic effectiveness.
Where this matters clinically
Effective half-life explains:
Why renal impairment may increase organ dose
Why hydration reduces bladder wall dose
Why tumour retention improves therapeutic response
Why some radionuclides are suitable for therapy and others are not
It also links radiopharmaceutical kinetics directly to internal dosimetry through the MIRD framework.